- Immunotherapy developer for cancer Scancell said it had signed a collaboration and research agreement with a US-based, clinical-stage antibody company that it did not identify.

The non-exclusive pact would see Scancell assess monoclonal antibodies targeting tumour-associated glycans, including those that had been enhanced with Scancell's proprietary AvidiMab technology.

The new collaboration partner would conduct pre-clinical studies to evaluate Scancell's anti-TaG mAbs for the treatment of cancer.

Story provided by